Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 18 September 2023 Vol. No. 12; Issue No. 596

1. Ravichandran G, Harijan D, Ganapathy N, Prabusankar G, De A, Rengan K (2023). The multifaceted role of degradable cobalt nanoparticles: Dual-target starvation and intracellular acidification engendering LC3-associated whole-cell autophagy. ACS Materials Letters.

2. Grover S, Lichter K, Likhacheva A, Jang J, Ning M, Robin T, Small W, Kudchadker R, Swamidas J, Chopra S, Rai B, Dutt Sharma S, Sharma D, Kuppusamy T, Yang R, Berger D, Mendez L, Glaser S, Erickson D, Chino J, Mourtada F, Abdel-Wahab M, Jhingran A, Simonds H, Mahantshetty U (2023). The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries. Brachytherapy.

3. Mahantshetty U, Kashid S, Mulye G, Gurram L, Engineer R, Chopra S, Ghosh J, Gulia S, Gupta S, Ghadi Y, Dheera A, Kohle S, Kadam S, Menon S, Deodhar K, Maheshwari A, Shylasree TS, Lewis S, Kalyani N, Shrivastava SK (2023). Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers. Brachytherapy.

4. Chatterjee G, Dhende P, Raj S, Shetty V, Ghogale S, Deshpande N, Girase K, Patil J, Kalra A, Narula G, Dalvi K, Dhamne C, Moulik NR, Rajpal S, Patkar NV, Banavali S, Gujral S, Subramanian PG, Tembhare PR (2023). 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges. European Journal of Haematology.

Saim Wasi Mulla. 2023. Proteasomal Chaperones and the Cross-Talk with NF-κB Signaling- An Integrated Network and Experimental approach. (LIFE09201404010) (Guide: Dr. Prasanna Venkatraman)

Site of the Week

SwissBioisostere is a database containing information on millions of molecular replacements and their performance in biochemical assays.

desktop Image
Interesting Reads

Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, Li X, Shen G, Peng J, Zheng P, Gu Y, Chen J, Lin M, Deng C, Gao H, Lu Z, Zhao Y, Luo M. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023

Video of the Week
Changing Epidemiology of Hepatocellular Carcinoma
Upcoming Events
1st National Symposium on Integrating Traditional Knowledge in Evidence Based Medicine

21-22 September, 2023

At Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai.

9th Trends in Head & Neck Oncology

09-11 November, 2023

At Málaga, Spain .

7th International Conference on Advanced Breast Cancer

09-11 November, 2023

At Lisbon, Portugal.

Do You Know?

In 2018, Cemiplimab (Libtayo) became the first approved therapy for patients with advanced cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer.

back Image
Cancer News
IISc scientists develop new approach to detect, kill cancer cells: Study

12 September 2023, NDTV

Have created hybrid nanoparticles made of gold and copper sulphide, which can kill cancer cells using heat, and enable their detection using sound waves…

Newfound stem cell might explain how breast cancer spreads to the spine

14 September 2023, Scientific American

New research in mice suggests that a stem cell involved in backbone development might help tumors from other parts of the body move to the spine...

Immunotherapy combination extends liver cancer patients’ survival, reveals study

15 September 2023, The Financial Express

According to the study, the immunotherapy Atezolizumab-bevacizumab combination has shown significant results in terms of overall and disease-free survival even complete resolution of tumors in certain cases when detected early and with timely treatment...

2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)